ENDRA Life Sciences (NDRA) Gains from Investment Securities: 2019-2021
Historic Gains from Investment Securities for ENDRA Life Sciences (NDRA) over the last 1 years, with Sep 2021 value amounting to $3.6 million.
- ENDRA Life Sciences' Gains from Investment Securities rose 880.38% to $3.6 million in Q3 2021 from the same period last year, while for Sep 2021 it was $3.6 million, marking a year-over-year increase of 6039.91%. This contributed to the annual value of $505,816 for FY2022, which is N/A change from last year.
- ENDRA Life Sciences' Gains from Investment Securities amounted to $3.6 million in Q3 2021, which was up 976.77% from $331,520 recorded in Q1 2021.
- ENDRA Life Sciences' Gains from Investment Securities' 5-year high stood at $3.6 million during Q3 2021, with a 5-year trough of -$424,210 in Q4 2019.
- For the 3-year period, ENDRA Life Sciences' Gains from Investment Securities averaged around $432,734, with its median value being $158,188 (2019).
- In the last 5 years, ENDRA Life Sciences' Gains from Investment Securities soared by 2,504.18% in 2020 and then fell by 15.95% in 2021.
- ENDRA Life Sciences' Gains from Investment Securities (Quarterly) stood at -$424,210 in 2019, then climbed by 14.17% to -$364,113 in 2020, then spiked by 880.38% to $3.6 million in 2021.
- Its Gains from Investment Securities was $3.6 million in Q3 2021, compared to $331,520 in Q1 2021 and -$364,113 in Q4 2020.